As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
PHE economist Jason Shafrin talks prices, politics, and the problem of monopolies with eyeforpharma’s Hugh Gosling.
Precision for Value’s Maureen Hennessey and Larry Blandford examine Medicare Advantage Five-Star Plans, focusing on innovation– in the this edition of Journal of Clinical Pathways (JCP).
PHE’s Mark Linthicum and Jason Shafrin discuss advancing the science of value assessment and the mission of the Innovation and Value Initiative in the latest edition of Genetic Engineering and Biotechnology News.
PHE Senior Research Economist Jason Shafrin’s latest Op-ed is featured in The Washington Post, as part of their “In Theory” series. The commentary, “How we should pay for cures, according to economics,” examines the current complexities of drug pricing and advocates for value-based pricing structures.
PHE Senior Research Economist Jason Shafrin presents an interesting picture of the value and pricing of precision medicine, in a new commentary for MedCity News.
Precision Health Economics founders Darius Lakdawalla and Dana Goldman contribute a new commentary for STAT News: “Election Verdict: Pharma Needs a New Prescription.”
Precision for Value’s Jeremy Schafer discusses managing biosimilars and the implications for health systems in a new article for Biosimilars Development.
Precision Health Economics’ Senior Research Economist Jason Shafrin provides an in-depth analysis of value frameworks in a new article for Pharmaceutical Commerce.
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”